explore -WSS

explore

author：hotspot 2025-09-27 19:38:13 - browse：8299

Light micrograph of a fatty liver — Large vacuoles of triglyceride fat, accumulated inside liver cells. Adobe

SAN DIEGO — An experimental obesity drug from Eli Lilly significantly reduced liver fat in a small analysis, supporting further studies of the treatment against nonalcoholic fatty liver disease, an increasingly common condition that lacks approved treatments.

Among 98 patients with nonalcoholic fatty liver disease, those on the highest dose tested of the drug, retatrutide, experienced an 86% decrease in liver fat over 48 weeks, with most of the reduction occurring early on in treatment, according to data presented here at the American Diabetes Association conference Monday.

Additionally, 93% of people on the highest dose achieved resolution of fatty liver disease, defined as having 5% or less liver fat.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Why getting cancer drugs just got harder for rural patients

entertainment

WSS

H5N1 virus can be tracked in retail milk, scientists say

FDA poised to publish guidelines for clinical trial diversity

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

Fentanyl is making it harder to start addiction treatment

H5N1 bird flu outbreak: Second human case reported, in Michigan

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

hotspot

explore

focus

FDA approval of Sarepta Duchenne genetic therapy gives me hope

As a primary care physician, here's how I hope to partner with AI

Trump demands the U.S. pay no more for drugs than other countries … again

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

Medicare proposal to cover medical devices draws a mixed reaction

RSV vaccines may be linked to small increased risk of developing GBS

Apple is now the first public company to be valued at $3 trillion

Questions and answers about ramping up H5N1 bird flu vaccine

Supreme Court strikes down use of affirmative action

UnitedHealth argues against case alleging wrongful AI care denials

explore

House looks to weaken Medicare negotiation

RSV vaccines may be linked to small increased risk of developing GBS

Readout Newsletter: H5N1 bird flu vaccine, Cytokinetics, Gilead

Flu vaccine offering decent levels of protection this winter, new data show

For longer

Eyeing GLP

leisure time

entertainment

hotspot

hotspot